Open AccessAssociation of Neurofilament Light With the Development and Severity of Parkinson Disease
Author(s) -
Shan Halloway,
Pankaja Desai,
Todd Beck,
Neelum T. Aggarwal,
Puja Agarwal,
Denis A. Evans,
Kumar B. Rajan
Publication year - 2022
Publication title -
neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.91
H-Index - 364
eISSN - 1526-632X
pISSN - 0028-3878
DOI - 10.1212/wnl.0000000000200338
Subject(s) - parkinsonism , parkinson's disease , biomarker , medicine , population , rating scale , neurodegeneration , disease , odds ratio , physical therapy , psychology , biology , environmental health , developmental psychology , biochemistry
Blood biomarkers may allow earlier identification of Parkinson disease (PD), parkinsonism, and poor PD-related outcomes, such as physical functioning. Neurofilament light (NfL), a neuronal cytoplasmic protein, is a biomarker of neurodegeneration measurable in biofluids. Our objective was to examine the association of serum NfL at baseline with clinically diagnosed PD, parkinsonian signs, and physical functioning change over 16 years in a population-based sample of older adults.